$195.03
+3.8%DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Acceptable margins but limited operational leverage. Operating expense control is important.
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Room for improvement: Moderate profitability with opportunities to enhance margins through better cost management or pricing strategy.
DVA โข NYSE
| DaVita Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
13.6B | 12.8B | 12.1B | 11.6B | 11.6B | 11.6B | 11.4B | 11.4B | 10.9B | 14.7B | 13.8B | 12.8B | 11.8B | 8.2B | 6.8B | 6.4B | 6.1B | 5.7B | 5.3B | 4.9B | |
GROSS PROFIT | ||||||||||||||||||||
(10B) | (8.6B) | (8.3B) | (8.2B) | (8B) | (8B) | (7.9B) | (8.2B) | (7.6B) | (7.4B) | (6.9B) | (9.1B) | (8.2B) | (5.6B) | (4.6B) | (4.4B) | (4.2B) | (3.9B) | (3.6B) | (3.4B) | |
3.7B | 4.2B | 3.8B | 3.4B | 3.6B | 3.6B | 3.5B | 3.2B | 3.2B | 3.3B | 3.1B | 3.7B | 3.6B | 2.6B | 2.1B | 1.8B | 1.9B | 1.7B | 1.7B | 1.5B | |
OPERATING INCOME | ||||||||||||||||||||
(1.7B) | (2.1B) | (2.2B) | (2.1B) | (1.8B) | (1.9B) | (1.8B) | (1.7B) | (1.4B) | (1.2B) | (2B) | (1.9B) | (2B) | (1.3B) | (943.5M) | (797.9M) | (919.9M) | (870.6M) | (811.6M) | (750.9M) | |
(1.7B) | (1.5B) | (1.5B) | (1.4B) | (1.2B) | (1.2B) | (1.1B) | (1.1B) | (1.1B) | (1.6B) | (1.5B) | (1.3B) | (1.2B) | (894.6M) | (691.2M) | (579M) | (531.5M) | (654.5M) | (627.9M) | (579.7M) | |
2B | 2.1B | 1.6B | 1.3B | 1.8B | 1.7B | 1.6B | 1.5B | 1.8B | 2B | 1.1B | 1.8B | 1.6B | 1.3B | 1.2B | 993.8M | 940.3M | 869.1M | 862.2M | 739.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(549.7M) | (470.5M) | (398.6M) | (357M) | (285.3M) | (304.1M) | (443.8M) | (487.4M) | (430.6M) | (414.4M) | (405.9M) | (410.3M) | (429.9M) | (0.0) | (241.1M) | (256M) | (185.8M) | (199.9M) | (157M) | (489M) | |
-549.7M | -470.5M | -398.6M | -357M | -285.3M | -304.1M | -443.8M | -487.4M | -430.6M | -414.1M | -405.9M | -507.8M | -429.9M | 288.5M | -241.1M | -256M | -185.8M | -224.7M | 0.0 | 0.0 | |
(0.0) | (588.2M) | (743.7M) | (706.1M) | (653.7M) | (619.8M) | (727.4M) | (548.1M) | (359.8M) | (173.3M) | (958.3M) | (599.2M) | (839.1M) | (415.8M) | (258.8M) | (226.1M) | (388.3M) | (362.4M) | (183.7M) | (171.2M) | |
-663.8M | -560.1M | -425.7M | -372.8M | -278.9M | -376.4M | -447.9M | -477.3M | -413M | -406.6M | -448.4M | -505.5M | -425.2M | -295.8M | -238.1M | -252.6M | -182M | -212.3M | -234.7M | -263.7M | |
1.3B | 1.5B | 1.2B | 966.3M | 1.5B | 1.3B | 1.2B | 1B | 1.4B | 1.5B | 723.1M | 1.3B | 1.1B | 1B | 892.7M | 744.5M | 758.2M | 609.5M | 627.5M | 475.8M | |
NET INCOME | ||||||||||||||||||||
(293.1M) | (279.7M) | (220.1M) | (198.1M) | (306.7M) | (313.9M) | (279.6M) | (258.4M) | (323.9M) | (455.8M) | (295.7M) | (446.3M) | (381M) | (359.8M) | (315.7M) | (260.2M) | (278.5M) | (235.3M) | (245.7M) | (186.4M) | |
746.8M | 936.3M | 691.5M | 560.4M | 978.5M | 773.6M | 811M | 159.4M | 663.6M | 879.9M | 269.7M | 723.1M | 633.4M | 536M | 478M | 405.7M | 422.7M | 374.2M | 381.8M | 289.7M |
DVA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 22, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 02, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 25, 2025 | November 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 29, 2025 | October 29, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 29, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 20, 2025 | August 20, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 05, 2025 | June 30, 2025 | 2025 |
Continue your DVA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.